Research Progress on the Improvement Effect and Mechanism of Probiotics on Colorectal Cancer

LIU Lijun; ZHANG Xiaotong; JIN Qiwen; LIU Fei; XIE Shuiqi; MENG Xiangchen

doi:10.13386/j.issn1002-0306.2021110067

Volume 43 Issue 21

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2022 > 43(21): 405-413. > DOI: 10.13386/j.issn1002-0306.2021110067

LIU Lijun, ZHANG Xiaotong, JIN Qiwen, et al. Research Progress on the Improvement Effect and Mechanism of Probiotics on Colorectal Cancer[J]. Science and Technology of Food Industry, 2022, 43(21): 405−413. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2021110067.

Citation:

PDF (1668 KB)

Research Progress on the Improvement Effect and Mechanism of Probiotics on Colorectal Cancer

Key Laboratory of Dairy Science, Ministy of Education, Northeast Agricultural University, Harbin 150030, China

More Information

Received Date: November 07, 2021
Available Online: August 20, 2022

Graphical Abstract

Abstract

Abstract

Colorectal cancer (CRC) is one of the most common types of cancer worldwide and the second leading cause of cancer-related death in the world. In recent years, the incidence of CRC has risen to the second place in China and more and more attention has been paid to its research. It has been found that the structure of intestinal flora is closely related to the occurrence and development of CRC. Probiotics, as a group of intestinal beneficial microorganisms, have the functions of regulating intestinal immunity, enhancing intestinal barrier and balancing of natural gut microflora. They play a significant role in the prevention and adjuvant therapy of CRC. This paper reviews the research progress on the effect of intestinal flora on CRC as well as the mechanism of probiotics on colorectal cancer, in order to lay a foundation for probiotics to prevent and alleviate CRC.
- colorectal cancer,
- gut microbiota,
- probiotics,
- chronic inflammation,
- mechanism

FullText(HTML)

References (79)

References

[1]	BICK B L, VEMULAPALLI K C, REX D K. Regional center for complex colonoscopy: Yield of neoplasia in patients with prior incomplete colonoscopy[J]. Gastrointestinal Endoscopy,2016,83(6):1239−1244. doi: 10.1016/j.gie.2015.10.053
[2]	FREDDIE B, JACQUES F, ISABELLE S, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians,2018,68(6):394−424. doi: 10.3322/caac.21492
[3]	王娜, 刘洁, 李晓东, 等. 中国1990~2019年结直肠癌疾病负担分析[J]. 中国循证医学杂志,2021,21(5):520−524. [WANG Na, LIU Jie, LI Xiaodong, et al. An analysis of disease burden of colorectal cancer in China from 1990 to 2019[J]. Chinese Journal of Evidence-Based Medicine,2021,21(5):520−524.
[4]	AÏCHA Z, JOSHUA R H, YANNICK D B. Intestinal microbiota influences DNA methylome and susceptibility to colorectal cancer[J]. Genes,2020,11(7):808. doi: 10.3390/genes11070808
[5]	SIEOW B F L, WUN K S, YONG W P, et al. Tweak to treat: Reprograming bacteria for cancer treatment[J]. Trends in Cancer,2020,7(5):447−464.
[6]	FONG Winnie, LI Qing, YU Jun. Gut microbiota modulation: A novel strategy for prevention and treatment of colorectal cancer[J]. Oncogene,2020,39(2S Suppl):4925−4943.
[7]	FLETCHER R, WANG Y J, SCHOEN R E, et al. Colorectal cancer prevention: Immune modulation taking the stage[J]. Biochimica et Biophysica Acta-Reviews on Cancer,2018,1869(2):138−148. doi: 10.1016/j.bbcan.2017.12.002
[8]	QIN J J, LI R Q, RAES J, et al. A human gut microbial gene catalogue established by metagenomicsequencing[J]. Nature: International Weekly Journal of Science,2010,464(7285):59−65.
[9]	SHIVAJI S. We are not alone: A case for the human microbiome in extra intestinal diseases[J]. Gut Pathogens,2017,9(1):13. doi: 10.1186/s13099-017-0163-3
[10]	KIM M, GALAN C, HILL A A, et al. Critical role for the microbiota in CX3CR1(+) intestinal mononuclear phagocyte regulation of intestinal T cell responses[J]. Immunity,2018,49(1):151−163. doi: 10.1016/j.immuni.2018.05.009
[11]	KARINA W, MAŁGORZATA S, RAFAŁ S. The role of the gut microbiome in colorectal cancer: Where are we? Where are we going?[J]. Clinical Colorectal Cancer,2020,19(1):5−12. doi: 10.1016/j.clcc.2019.07.006
[12]	EATON K, PIRANI A, SNITKIN E S. Replication study: Intestinal inflammation targets cancer-inducing activity of the microbiota[J]. eLife,2018,7:e34364. doi: 10.7554/eLife.34364
[13]	ANNEMARIE B, HAROLD T. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease[J]. The Lancet Infectious Diseases,2013,13(8):719−724. doi: 10.1016/S1473-3099(13)70107-5
[14]	SHEN Xiaonan, LI Jialu, LI Jiaqi, et al. Fecal enterotoxigenic Bacteroides fragilis-Peptostreptococcus stomatis-Parvimonas micra biomarker for noninvasive diagnosis and prognosis of colorectal laterally spreading tumor[J]. Frontiers in oncology,2021,11:661048. doi: 10.3389/fonc.2021.661048
[15]	KOMIYA Y, SHIMOMURA Y, HIGURASHI T, et al. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity[J]. Gut,2019,68(7):1335−1337. doi: 10.1136/gutjnl-2018-316661
[16]	LI Xiang, HUANG Jiepeng, YU Tingting, et al. Fusobacterium nucleatum promotes the progression of colorectal cancer through Cdk5-activated Wnt/beta-catenin signaling[J]. Frontiers in Microbiology,2021,11:545251. doi: 10.3389/fmicb.2020.545251
[17]	KIM S H, LIM Y J. The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment[J]. Intestinal Research,2021,20(1):31−42.
[18]	LIANG Q Y, JONATHAN C, CHEN Y X, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer[J]. Clinical Cancer Research,2017,23(8):2061−2070. doi: 10.1158/1078-0432.CCR-16-1599
[19]	SI Huifang, YANG Qing, HU Hong, et al. Colorectal cancer occurrence and treatment based on changes in intestinal flora[J]. Seminars in Cancer Biology,2021,70:13−10.
[20]	WONG S H, YU J. Gut microbiota in colorectal cancer: Mechanisms of action and clinical applications[J]. Nature Reviews Gastroenterology & Hepatology,2019,16(11):690−704.
[21]	PARK C H, EUN C S, HAN D S. Intestinal microbiota, chronic inflammation, and colorectal cancer[J]. Intestinal Research,2018,16(3):338−345. doi: 10.5217/ir.2018.16.3.338
[22]	BASHIR A, MISKEEN A Y, BHAT A, et al. Fusobacterium nucleatum: An emerging bug in colorectal tumorigenesis[J]. European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP),2015,24(5):373−85. doi: 10.1097/CEJ.0000000000000116
[23]	HUA X, PHIPPS A I, BURNETT-HARTMAN A N, et al. Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology,2017,35(24):2806−2813. doi: 10.1200/JCO.2017.72.3569
[24]	HERBERT T, TIMON E A, ROMANA R G, et al. The intestinal microbiota in colorectal cancer[J]. Cancer Cell,2018,33(6):954−964. doi: 10.1016/j.ccell.2018.03.004
[25]	LAVOIE S, GARRETT W S. The unfolding story of ATF6, microbial dysbiosis, and colorectal cancer[J]. Gastroenterology,2018,155(5):1309−1311. doi: 10.1053/j.gastro.2018.10.011
[26]	CHRISTINE M D, PAYAM F, JOHN M C, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria[J]. Science,2018,359(6375):592−597. doi: 10.1126/science.aah3648
[27]	HO T, EAGLE SH, ZHANG X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice[J]. Gastroenterology,2017,152(5):S1010−S1010.
[28]	LONG Xiaohang, WONG Chichun, LI Tong, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumourimmunity[J]. Nature Microbiology,2019,4(12):2319−2330. doi: 10.1038/s41564-019-0541-3
[29]	YU Tachung, GUO Fangfang, YU Yanan, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell,2017,170(3):548−563. doi: 10.1016/j.cell.2017.07.008
[30]	KYLE W. D, VINEETA K, MICHAELA L, et al. Tu1674 PAK1 mediates NF-κB signaling in colitis and colitis-associated cancer[J]. Gastroenterology,2013,144(5):S819−S819.
[31]	JESÚS C R, DOLORES O M, SARA C, et al. M2 macrophages activate WNT signaling pathway in epithelial cells: Relevance in ulcerative colitis[J]. PLoS ONE,2017,8(10):e78128.
[32]	TENG Jiaan, WU Sangang, CHEN Jiaxin, et al. The activation of ERK1/2 and JNK MAPK signaling by insulin/IGF-1 is responsible for the development of colon cancer with type 2 diabetes mellitus[J]. PloS ONE,2016,11(2):e0149822. doi: 10.1371/journal.pone.0149822
[33]	YE Xiaohong, WU Hua, SHENG Luoyan, et al. Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling[J]. Nature Communications,2019,10(1):793−810. doi: 10.1038/s41467-019-08689-x
[34]	CHUNG I C, OUYANG C N, YUAN S N, et al. Pretreatment with a heat-killed probiotic modulates the NLRP3 inflammasome and attenuates colitis-associated colorectal cancer in mice[J]. Nutrients,2019,11(3):516−516. doi: 10.3390/nu11030516
[35]	VIDHYASAGAR V, JEEVARATNAM K. Evaluation of Pediococcus pentosaceus strains isolated from Idly batter for probiotic properties in vitro[J]. Journal of Functional Foods,2013,5(1):235−243. doi: 10.1016/j.jff.2012.10.012
[36]	GAREAU M G, SHERMAN P M, WALKER W A. Probiotics and the gut microbiota in intestinal health and disease.[J]. Nature Reviews. Gastroenterology & Hepatology,2010,7(9):503−514.
[37]	ZHONG Li, ZHANG Xufei, COVASA M. Emerging roles of lactic acid bacteria in protection against colorectal cancer[J]. World Journal of Gastroenterology,2014,20(24):7878−7886. doi: 10.3748/wjg.v20.i24.7878
[38]	WANG Chunsaier, LI Wenbin, WANG Hongying, et al. VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice[J]. World Journal of Gastroenterology,2018,24(37):4254−4262. doi: 10.3748/wjg.v24.i37.4254
[39]	MARIA M, DAIANE P, SANDRA R B, et al. Microbiota modification by probiotic supplementation reduces colitis associated colon cancer in mice[J]. World Journal of Gastroenterology,2018,24(18):1995−2008. doi: 10.3748/wjg.v24.i18.1995
[40]	DENISE S, LUCIANA V, LUÍS L, et al. Lactobacillus bulgaricus inhibits colitis-associated cancer via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium sulfate model[J]. World Journal of Gastroenterology,2020,26(43):6782−6794. doi: 10.3748/wjg.v26.i43.6782
[41]	JACOUTON E, CHAIN F, SOKOL H, et al. Probiotic strain Lactobacillus casei BL23 prevents colitis-associated colorectal cancer[J]. Frontiers in Immunology,2017,8:1553. doi: 10.3389/fimmu.2017.01553
[42]	WALIA S, KAMAL R, DHAWAN D K, et al. Chemoprevention by probiotics during 1, 2-dimethylhydrazine-induced colon carcinogenesis in rats[J]. Digestive Diseases and Sciences,2018,63(4):900−909. doi: 10.1007/s10620-018-4949-z
[43]	GOLKHALKHALI B, RAJANDRAM R, PALIANY A S, et al. Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: A randomized controlled trial[J]. Asia-Pacific Journal of Clinical Oncology,2018,14(3):179−191. doi: 10.1111/ajco.12758
[44]	YANG Yongzhi, XIA Yang, CHEN Hongqi, et al. The effect of perioperative probiotics treatment for colorectal cancer: Short-term outcomes of a randomized controlled trial[J]. Oncotarget,2016,7(7):8432−40. doi: 10.18632/oncotarget.7045
[45]	LIYANA Z, NORFILZA M, KHAIRUL N, et al. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer[J]. BMC Gastroenterology,2019,19(1):1−8. doi: 10.1186/s12876-018-0926-4
[46]	GAO Zhiguang, GUO Bomin, GAO Renyuan, et al. Probiotics modify human intestinal mucosa-associated microbiota in patientswith colorectal cancer[J]. Molecular Medicine Reports,2015,12(4):6119−6127. doi: 10.3892/mmr.2015.4124
[47]	KIM Y, LEE D, KIM D, et al. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium addlescentis SPM0212[J]. Archives of Pharmacal Research,2008,31(4):468−473. doi: 10.1007/s12272-001-1180-y
[48]	PETRA L, HARRY J F. Formation of propionate and butyrate by the human colonic microbiota[J]. Environmental Microbiology,2017,19(1):29−41. doi: 10.1111/1462-2920.13589
[49]	OHARA T, SUZUTANI T. Intake of Bifidobacterium longum and fructo-oligosaccharides prevents colorectal carcinogenesis[J]. Euroasian Journal of Hepato-gastroenterology,2018,8(1):11−17. doi: 10.5005/jp-journals-10018-1251
[50]	STEPHEN W F. Promoting apoptosis as a strategy for cancer drug discovery[J]. Nature Reviews Cancer,2005,5(Suppl):876−885.
[51]	CHONDROU P, KARAPETSAS A, KIOUSIDE, et al. Lactobacillus paracasei K5 displays adhesion, anti-proliferative activity and apoptotic effects in human colon cancer cells[J]. Beneficial Microbes,2018,9(6):975−983. doi: 10.3920/BM2017.0183
[52]	FOO N P, OU Y H, CHIU H H, et al. Probiotics prevent the development of 1, 2-dimethylhydrazine (DMH)-induced colonic tumorigenesis through suppressed colonic mucosa cellular proliferation and increased stimulation of macrophages[J]. Journal of Agricultural and Food Chemistry,2011,59(24):13337−13345. doi: 10.1021/jf203444d
[53]	GUO Yuxing, ZHANG Tao, GAO Jinjin, et al. Lactobacillus acidophilus CICC 6074 inhibits growth and induces apoptosis in colorectal cancer cells in vitro and in HT-29 cells induced-mouse model[J]. Journal of Functional Foods,2020,75:104290. doi: 10.1016/j.jff.2020.104290
[54]	BALDWIN C, MILLETTE M, OTH D, et al. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis[J]. Nutrition and Cancer,2010,62(3):371−8. doi: 10.1080/01635580903407197
[55]	FAGHFOORI Z, FAGHFOORI M H, SABER A, et al. Anticancer effects of Bifidobacteria on colon cancer cell lines[J]. Cancer Cell International,2021,21(1):258−258. doi: 10.1186/s12935-021-01971-3
[56]	GEORGIA S, ATHANASIOS K, ELEFTHERIA L, et al. Two potential probiotic Lactobacillus strains isolated from olive microbiota exhibit adhesion and anti-proliferative effects in cancer cell lines[J]. Journal of Functional Foods,2016,24:461−471. doi: 10.1016/j.jff.2016.04.036
[57]	GAKURO H, PAWAT P, KENJI I, et al. Lactobacillus brevis T2102 suppresses the growth of colorectal cancer cells by activating SIRT1[J]. Journal of Functional Foods,2016,23:444−452. doi: 10.1016/j.jff.2016.01.016
[58]	NOBUHIRO H, SHUJI K, KOUHEI O, et al. Extract of Lactobacillus plantarum strain 06CC2 induces JNK/p38 MAPK pathway-mediated apoptosis through endoplasmic reticulum stress in Caco2 colorectal cancer cells[J]. Biochemistry and Biophysics Reports,2019,20:100691. doi: 10.1016/j.bbrep.2019.100691
[59]	HOSSEINI S, GOUDARZI H, GHALAVAND Z, et al. Anti-proliferative effects of cell wall, cytoplasmic extract of Lactococcuslactis and nisin through down-regulation of cyclin D1 on SW480 colorectal cancer cell line[J]. Iranian Journal of Microbiology,2020,12(5):424−430.
[60]	ANGELIKI T K, KATERINA S, VALENTINA S, et al. Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells[J]. PLoS ONE,2017,11(2):e0147960.
[61]	JONATHAN L, EMMA R, NICK E, et al. Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer[J]. World Journal of Gastroenterology,2016,22(11):3117−3126. doi: 10.3748/wjg.v22.i11.3117
[62]	BORJA S, SUSANA D, AITOR B M, et al. Probiotics, gut microbiota, and their influence on host health and disease[J]. Molecular Nutrition & Food Research,2017,61(1):1−15.
[63]	HAJJAR R, RICHARD C S, SANTOS M. The role of butyrate in surgical and oncological outcomes in colorectal cancer[J]. American Journal of Physiology. Gastrointestinal and Liver Physiology,2021,320(4):G601−G608. doi: 10.1152/ajpgi.00316.2020
[64]	EUGENE D K, XUEQI S, YASER G, et al. Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer[J]. Digestive Diseases and Sciences,2016,61(10):2908−2920. doi: 10.1007/s10620-016-4238-7
[65]	杨洋, 赵勇. 丙氨酰谷氨酰胺及双歧杆菌三联活菌胶囊在结直肠癌术后辅助化疗中对肠道屏障功能的影响[J]. 中国现代医学杂志,2020,30(15):79−84. [YANG Yang, ZHAO Yong. Effect of alanyl glutamine and Bifidobacterium triple viable capsule on intestinal barrier function in postoperative adjuvant chemotherapy for colorectal cancer[J]. China Journal of Modern Medicine,2020,30(15):79−84. doi: 10.3969/j.issn.1005-8982.2020.15.015
[66]	EHUD Z, CHEN V, JULIA F, et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells[J]. Immunity,2012,37(6):1076−1090. doi: 10.1016/j.immuni.2012.08.026
[67]	MAJID E, BAHMAN Y, PARVIZ K I, et al. Importance of probiotics in the prevention and treatment of colorectal cancer[J]. Journal of Cellular Physiology,2019,234(10):17127−17143. doi: 10.1002/jcp.28473
[68]	RAJA A, LIYANA Z, SEOW-NENG C, et al. Sa1838-The clinical and circulating inflammatory cytokines effects of probiotic containing Lactobacillus and Bifidobacterium strains in patients with colorectal cancer: A randomized double blind controlled trial[J]. Gastroenterology,2018,154(6):S414−S414.
[69]	CINDERELLA A F, AMIRA M G, ENAS A E, et al. Bifidobacterium longum suppresses murine colorectal cancer through the modulation of oncomiRs and tumor suppressor miRNAs[J]. Nutrition and Cancer,2019,71(4):688−700. doi: 10.1080/01635581.2019.1577984
[70]	LIU Meiling, ZHANG Xiuxia, HAO Yunpeng, et al. Protective effects of a novel probiotic strain, Lactococcuslactis ML2018,in colitis: In vivo and in vitro evidence[J]. Food & Function,2019,10(2):1132−1145.
[71]	FENG Tao, WANG Jing. Oxidative stress tolerance and antioxidant capacity of lactic acid bacteria as probiotic: A systematic review[J]. Gut Microbes,2020,12(1):1801944. doi: 10.1080/19490976.2020.1801944
[72]	ADRIANA N, ANNA P, JANUSZ B. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives[J]. Critical Reviews in Food Science and Nutrition,2019,59(21):3456−3467. doi: 10.1080/10408398.2018.1494539
[73]	AHMAD U D, ADIL H, YUAN Z, et al. Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism[J]. The Journal of Nutritional Biochemistry,2020,79:108353. doi: 10.1016/j.jnutbio.2020.108353
[74]	CHANG C Y, HO B Y, PAN T M. Lactobacillus paracasei subsp. paracasei NTU 101-fermented skim milk as an adjuvant to uracil-tegafur reduces tumor growth and improves chemotherapy side effects in an orthotopic mouse model of colorectal cancer[J]. Journal of Functional Foods,2019,55:36−47. doi: 10.1016/j.jff.2019.02.025
[75]	TANG Gang, ZHANG Linyu. Update on strategies of probiotics for the prevention and treatment of colorectal cancer[J]. Nutrition and Cancer,2020,74(1):27−38. doi: 10.1080/01635581.2020.1865420
[76]	JANELLE C, RAAD Z G, JOSHUA M U, et al. VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer[J]. Scientific Reports,2013,3(1):728−734.
[77]	JACQUELINE H S, PETER J H. Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome[J]. ANZ Journal of Surgery,2012,82(6):420−427. doi: 10.1111/j.1445-2197.2012.06082.x
[78]	JAN F, SHANKAR R, NIVEDITA K, et al. Randomized trial of perioperative probiotics among patients undergoing major abdominal operation[J]. Journal of the American College of Surgeons,2019,229(6):533−540. doi: 10.1016/j.jamcollsurg.2019.09.002
[79]	PITSILLIDES L, PELLINO G, TEKKIS P, et al. The effect of perioperative administration of probiotics on colorectal cancer surgery outcomes[J]. Nutrients,2021,13(5):1451−1451. doi: 10.3390/nu13051451

Supplements (0)

Cited By

Cited by

Periodical cited type(6)

1.	李杰，李霜，张鹏霞，祝丽玲，周健，孙雪微，宋丽新. 发酵食品中具有潜在降尿酸功能乳酸菌的筛选及特性分析. 食品研究与开发. 2024(07): 174-180 .
2.	于鑫迪，刘静雅，任秀梅，陈炼红. 功能性牦牛酸奶制备、贮藏期内品质及降嘌呤活性研究. 食品工业科技. 2024(21): 20-29 . 本站查看
3.	莫星忧，欧仕益，毋福海，吴帅，吴慧，李倩. 膳食对高尿酸血症的影响及控制研究进展. 农产品加工. 2024(22): 100-104 .
4.	陈天琦，屈墨涵，张春红，李丹，尹雪斌. 食药同源对防治慢性代谢性疾病的作用及功能农业解决方案. 肥料与健康. 2024(06): 86-90 .
5.	付喜华，韩四海，刘建学，李佩艳，郭金英，罗登林，岳崇慧. 葡萄蒸馏酒对高尿酸血症模型小鼠肠道菌群的调节作用. 食品科学. 2023(07): 161-168 .
6.	陈聪聪，周全. 基于网络药理学与分子对接探讨四妙丸“异病同治”强直性脊柱炎和高尿酸血症的作用机制. 河南中医. 2023(10): 1534-1542 .